55 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business … interruptions including any adverse impacts on our ability to obtain raw materials and test animals as well as similar problems with our vendors and our
8-K/A
EX-99.4
COCP
Cocrystal Pharma Inc
15 Sep 11
Financial Statements and Exhibits
12:00am
. It sells pharmaceutical raw materials to BioZone Laboratories, Inc. (“BioZone Labs”), an entity that has substantially common ownership … losses in such accounts
Revenue Recognition
The Company operates as a reseller of pharmaceutical raw materials and licensor of intellectual property
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
24 Apr 23
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
8:13am
, and on the U.S., U.K., Australia and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain … disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials and test animals as well as similar
8-K
EX-99.1
6zdir58eeb5 flfx5
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
kzlz977
7 Jul 11
Acquires Biozone Laboratories, Inc. and Related Companies
12:00am
8-K
EX-99.1
ut8jago 2o9kf0f
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
d7dsxl
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
8-K
EX-99.1
73ieyb cijlt
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
x6hlwe p1e9zaawen
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
mz6 htle4fc08e6p2ag
28 Mar 13
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
66chfk uk
22 Dec 21
Regulation FD Disclosure
8:30am
S-1
tjwtw2nxogv jem
21 Sep 11
IPO registration
12:00am
424B7
p89a kc0en
26 Feb 13
Prospectus with selling stockholder info
12:00am